Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Pulsatile Drug Delivery System:An Overview with Special Emphasis on Losartan and Captopril


Affiliations
1 Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao (U.P.), India
     

   Subscribe/Renew Journal


In the current scenario of pharmaceutical research much attention has been focused on patients’ health in terms of therapeutic efficacy and safety so keeping this thing in mind, the objective of the study is to make an attempt to control the tradition of prescribing the doses of medication throughout a period of 24 hours as different researches have given the idea of administration of medications with day-night pattern and biological rhythms to reduce the dose frequency. Pulsatile drug delivery system is designed according to the circadian rhythm of the body, and the drug is released rapidly and completely as a pulse after a lag time. Products follow the sigmoid release profile characterized by a time period. This delivery system follow chronopharmacological behavior, where night-time dosing is required, and for drugs that show the first-pass effect. This review article was designed to throw light on marketed techniques of pulsatile drug delivery and to investigate the pulsatile release of Losantan and Captopril, based on chronotherapeutic consideration. The principle rationale for the use of pulsatile release of the drugs is where a constant drug release is not required and drug delivery should be such that there is complete drug release after a lag time. Lag time is defined as the time between when a dosage form is placed into an aqueous environment and the time at which the active ingredient begins to get released from the dosage form. This article focuses on the importance of pulsatile drug delivery system along with the study of different pulsatile release dosage forms containing Losartan (ARB-Angiotensin Receptor Blocker) and Captopril (ACE inhibitor-Angiotensin Converting Enzyme inhibitor).

Keywords

Pulsatile Release, Chronopharmacotherapy, Lags Time, Losartan, Captopril.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Vaniprasanna Tubati et al. An Over View of Chronotherapeutic Drug Delivery Systems Based on Floating Pulsatile Concept. Journal of Advances in Medical and Pharmaceutical. 2016, 7(3):1-18.

  • Singh HN, Saxena S, Singh S, Yadav AK. Pulsatile Drug Delivery System: Drugs used in the Pulsatile Formulations. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013, 5(3):115-121.

  • Dhengale AA, Darekar AB, Saudagar RB. A Review: Pulsatile Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2016, 8(3): 221-227.

  • Patil IS, Patil OA, Mandake GC, Nitalikar MM. Development and Evaluation of Telmisartan Pulsatile Drug Delivery by using Response Surface Methodology. Asian Journal of Pharmaceutical Research. 2018, 8(4): 205-14.

  • Baghel P, Roy A, Chandrakar S, Bahadur S. Pulsatile Drug Delivery System: A Promising Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013, 5(3): 111-114.

  • Guo ZX, Qiu MC. Losartan down regulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat. Zhonghua NeiKe ZaZhi. 2003, 42(6): 403-8.

  • Lemmer B. Chronopharmacokinetics: Implications for drug treatment. Journal of Pharmacy and Pharmacology. 1999, 51: 887-890.

  • Sukanya M, Saikishore V, Shanmukha PY, Srikanth K. Novel Approaches for Pulsatile Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology.2012, 4(4): 197-201.

  • Trivedi RV et al. Chronotherapy: A concept, pauperism and approches. International Journal of Pharmaceutical Development and Technology. 2011, 1(1):1-10

  • Sudhamani T et al. Chronotherapeutic floating pulsatile drug delivery: An approach for time specific and site specification absorption of drugs. Research Journal of Pharmaceutical Technology. 2011, 4(5): 685-690.

  • Evans RM, Marain C. Taking your medication: A question of timing. American Medical Association 1996, 3-8.

  • Li JJ. Circardian variation in myocardial ischemia: The possible mechanisms involving in this phenomenon. Med Hypotheses. 2003, 61(2): 240-243.

  • Nainwal Nidhi, Chronotherapeutics: A chronopharmaceutical approach to drug delivery in the treatment of asthma. Journal of Controlled Release. 2012, 163(3):353-360.

  • Saigal Nitin, Baboota Sanjula, Ahuja Alka, Ali Javed. Site specific chronotherapeutic drug delivery system: A patent review. Recent patents on drug delivery and formulation. 2009: 64-70.

  • Tangri P, Khurana S. Pulsatile drug delivery systems: Methods and advances. International Journal of Drug Formulation and Research. 2011, 2(3):100-114.

  • Bhandawalkar K, et al. Recent trends in pulsatile drug delivery systems: A review. International Journal of Institutional Pharmacy and Life Sciences. 2002, 2(3): 167-185.

  • Singh NP, Ganarajan G, Kothiyal P. Pulsatile drug delivery system: a review. World Journal Pharmacy Pharmaceutical Sciences.2016, 5:479-491.

  • Dalvadia H, Patelb JK. Chronpharmaceutics, pulsatile drug delivery system as current trend. Asian journal of pharmaceutical sciences. 2010, 5(5):204-30.

  • Herold M, Günther R. Circadian rhythm of C-reactive protein in patients with rheumatoid arthritis. Progress in clinical and biological research. 1987, 227:271-9.

  • Martin RJ, Banks SS. Chronobiology of asthma. American Journal of Respiratory Critical Care Medicine.1998; 158:1002–1007.

  • Arkinstall WW. Review of the North American experience with evening administration of Uniphyl tablets, a once daily theophylline. The American Journal of Medicine. 1994, 85(1): 521–524.

  • Bogin RM, Ballard RD. The treatment of nocturnal asthma with pulsed release albuterol. Chest.1992, 102: 362-366.

  • Khamidov N, Zaslavskaia RM, Arustamian GS. The daily dynamics of blood lipids in elderly subjects with hypertension. Laboratornoedelo.1990, (11):47-50.

  • Hulcher FH, Reynolds J, Rose JC. Circadian rhythm of HMG-CoA reductase and insulin in African green monkeys. Biochemistry international. 1985;10 (2):177-85.

  • Mayer D. The circadian rhythm of synthesis and catabolism of cholesterol. Archives of toxicology.1976, 36(2-4): 267–276

  • Rigas AN, Bittles AH, Hadden DR, Montgomery DA. Circadian variation of glucose, insulin, and free fatty acids during long-term use of oral hypoglycemic agents in diabetes mellitus. British Medical Journal. 1968, 4(5622): 25-8.

  • Cincotta AH, Meier AH. Circadian rhythms of lipogenic and hypoglycaemic responses to insulin in the golden hamster (Mesocricetus auratus).Journal of endocrinology. 1984, 103(2):141-6.

  • Humphries TJ, Root JK, Hufnagel K. Successful drug specific chronotherapy with the H2 blocker famotidine in the symptomatic relief of gastro esophageal reflux disease. Annals of the New York Academy of Sciences. 1991, 618(1):517.

  • Lemmer B. Cardiovascular chronobiology and chronopharmacology. Biological Rhythms in Clinical and Laboratory Medicine. 1992, 2:418-427.

  • Tofler GH et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. New England Journal of Medicine. 1987,, 316(24):1514-8.

  • Libo Y, James L, Joseph A. Colonic-specific drug delivery: new approaches and Invitro/invivo evaluation. International Journal of Pharmacy. 2002;235:1-15.

  • Reddy JR et al. Pulsatile Drug Delivery System. Journal of Pharmaceutical Science and Research. 2009; 1(4): 109-115.

  • Ueda T et al. Development of Novel Drug Delivery System, Time Controlled Explosion System (TES). I. Concept and design. Journal of drug targeting. 1994;2(2):133-40.

  • Baker R.W. Controlled release delivery system by an osmotic bursting mechanism. US Patent. 1976; 3,952,741.

  • Schultz P, Kleinebudde P. A new multiparticulate delayed release system: Part I: dissolution properties and release mechanism. Journal of controlled release. 1997;47(2):181-9.

  • Morita R, Hunda Y, Takahashi R. Development of Oral Controlled Release Preparation; I. Design of SCAR and Its Release Controlling Factor. Journal of Controlled Release. 2000:279-309.

  • Gennaro AR, ed. Remington: The Science and Practice of Pharmacy. 20th ed. USA: Lippincott. Williams and Wilkins.2000; 20: 903-905.

  • Das NG, Das SK. Controlled release of oral dosage forms. Pharmaceutical technology. 2003; 15:10-7.

  • Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. International Journal of Pharmaceutics. 1993; 95(1-3):193-9.

  • Evans DF et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035-41.

  • Gurny R, Junginger HE, Peppas NA. Pulsatile drug delivery (current applications and future trends). Paperback APV. Stuttgart, Germany. 1993.

  • Ibekwe VC, Kendall RA, Basit AW. Drug delivery to the colon. The Drug Delivery Companies Report, Spring/Summer, Pharmaventures Ltd. 2004.

  • Takaya T et al. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) in beagle dogs. Journal of pharmacy and pharmacology. 1995;47(6):474-8.

  • Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. Critical Review. The Drug Carrier System. 200;18(5): 433-58.

  • Daumesnil R. Marketing Considerations for multiparticulate drug delivery systems. Drugs and the pharmaceutical sciences. 1994; 65:457-74.

  • Schultz P, Tho I, Kleinebudde P. A new multiparticulate delayed release system.: Part II: coating formulation and properties of free films. Journal of controlled release. 1997;47 (2):191-9.

  • Chen CM. Multiparticulate Pulsatile Drug Delivery System. US Patent No. 5,508,040; 1996.

  • Schultz P, Kleinebudde P. A new multiparticulate delayed release system. Part I: Dissolution properties and release mechanism. Journal of controlled release.1997; 47: 181-189.

  • Sungthongjeen S, Puttipipatkhachorn S, Paeratakul O, Dashevsky A, Bodmeier R. Development of pulsatile release tablets with swelling and rupturable layers. Journal of controlled release. 2004;95(2):147-59.

  • Survase S, Kumar N. Pulsatile Drug Delivery Current Scenario. CRIPS 2007; 8(2): 27-33.

  • MacNeil ME, Rashid A, Stevens HN. Dispensing device.World Patent 1990; 9009168.

  • Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. Journal of controlled release. 2009;134(2):74-80.

  • Troy M. Timing drug availability with therapeutic need. Speciality pharma. 2004; 2:44-7.

  • Bhatt Ashvin D, Pethe AM. Lipid Technology-A Promising Drug Delivery System For Poorly Water Soluble Drugs. International Journal of Pharma Research and Development. 2010; 1:1-11.

  • Verma RK, Garg S. Drug delivery technologies and future directions. Pharmaceutical Technology. 2001; 25(2):1-4.

  • Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter. 2011 Jul 1; 1(1):57-65.

  • Nayakulu BR, Kumar NR, Kumar CK, Abhilash PR. Formulation and evaluation of floating matrix tablet of Losartan for gastroretentive drug delivery. Asian Journal of Pharmacy and Technology. 2016;6(2):85-90.

  • Ashwini MS, Ahmed MG. Design and evaluation of Pulsatile drug delivery of Losartan Potassium. Dhaka University Journal of Pharmaceutical Sciences. 2013;12(2):119-23.

  • Bojja R, Satyanandam R. Design and Development of Pulsincap for Chronopharmaceutical Drug Delivery of Losartan Potassium. Asian Journal of Pharmaceutical Research and Development. 2014; 2(3):78-86.

  • Latha K et al. Development of an Optimized Losartan Potassium Press-Coated Tablets for Chronotherapeutic Drug Delivery. Tropical Journal of Pharmaceutical Research. 2011; 10(5): 551-558.

  • Shivhare UD, Kakade VN. Formulation and Evaluation of Pulsatile Drug Delivery System of Losartan Potassium by Factorial Design. International Journal of pharmaceutical Sciences and Nanotechnology. 2013;5 (4):1895-1901.

  • Bajpai M et al. Design and In Vitro Evaluation of Compression-coated Pulsatile Release Tablets of Losartan Potassium. Indian Journal of Pharmaceutical Sciences. 2012;74(2): 101–106.

  • Sravani SL, Saikishore V, Saikrishna MV. Design and Characterization of Pulsatile Drug Delivery of Losartan Potassium. Indo American Journal of Pharmaceutical Sciences. 2017; 4(3):706-712.

  • Madgulkar A, Bhalekar M, Swami M. In Vitro and In Vivo Studies on Chitosan Beads of Losartan Duolite AP143 Complex, Optimized by Using Statistical Experimental Design. American Association of Pharmaceutical Scientists. 2009;10(3):743-751.

  • Nagaraja G et al. Design and evaluation of time programmed pulsincap system for chronotherapeutic delivery of losartan potassium. Journal of Chemical and Pharmaceutical Research. 2013;5(6):76-87.

  • Murthy TE, Madalasa AL. Design and Development of Oral Modified Release Formulations for Losartan Potassium with Natural and Modified Gums. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018;10(3):149-56.

  • Noman MA, Albooryhi M, Sayf AA, Kadi HO. In-vitro evaluation of captopril tablets present in Yemen markets. Research Journal of Pharmaceutical Dosage Forms and Technology. 2012;4(2):124-7.

  • Gadad AP et al. Design and characterization of hollow/porous floating beads of captopril for pulsatile drug delivery. Asian Journal of Pharmaceutics. 2012:137-143.

  • Thampi NK et al. Formulation, Optimization and Evaluation of Floating Pulsatile Beads of Captopril. World Journal of Pharmacy and Pharmaceutical Sciences. 2017; 6(6):1619-1637.

  • Meka L et al. Preparation of a Matrix Type Multiple-Unit Gastro Retentive Floating Drug Delivery System for Captopril Based on Gas Formation Technique: In Vitro Evaluation. AAPS Pharm Sci Tech. 2008;9(2):612.

  • Kapoor D, Patel R et al. Formulation, Optimization and Evaluation of Floating Microspheres of Captopril. Asian Journal of Biomedical and Pharmaceutical Sciences. 2012;2(9) :1-10.

  • Thadkala K, Prathyusha R, Raju A et al. Formulation Development, Optimization and Characterization of Floating Beads of Captopril. International Journal of Pharmaceutical Research and Allied Sciences. 2013; 2(2):32-46.

  • Basawaraj S. Patil, et at. Formulation and in-vitro evaluation of Captopril floating matrix tablets. Journal of Pharmacy Research. 2012; 5 (2).803-806


Abstract Views: 382

PDF Views: 0




  • Pulsatile Drug Delivery System:An Overview with Special Emphasis on Losartan and Captopril

Abstract Views: 382  |  PDF Views: 0

Authors

Hema Jaiswal
Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao (U.P.), India
Vaseem Ahamad Ansari
Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao (U.P.), India
J. N. Pandit
Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao (U.P.), India
Farogh Ahsan
Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao (U.P.), India

Abstract


In the current scenario of pharmaceutical research much attention has been focused on patients’ health in terms of therapeutic efficacy and safety so keeping this thing in mind, the objective of the study is to make an attempt to control the tradition of prescribing the doses of medication throughout a period of 24 hours as different researches have given the idea of administration of medications with day-night pattern and biological rhythms to reduce the dose frequency. Pulsatile drug delivery system is designed according to the circadian rhythm of the body, and the drug is released rapidly and completely as a pulse after a lag time. Products follow the sigmoid release profile characterized by a time period. This delivery system follow chronopharmacological behavior, where night-time dosing is required, and for drugs that show the first-pass effect. This review article was designed to throw light on marketed techniques of pulsatile drug delivery and to investigate the pulsatile release of Losantan and Captopril, based on chronotherapeutic consideration. The principle rationale for the use of pulsatile release of the drugs is where a constant drug release is not required and drug delivery should be such that there is complete drug release after a lag time. Lag time is defined as the time between when a dosage form is placed into an aqueous environment and the time at which the active ingredient begins to get released from the dosage form. This article focuses on the importance of pulsatile drug delivery system along with the study of different pulsatile release dosage forms containing Losartan (ARB-Angiotensin Receptor Blocker) and Captopril (ACE inhibitor-Angiotensin Converting Enzyme inhibitor).

Keywords


Pulsatile Release, Chronopharmacotherapy, Lags Time, Losartan, Captopril.

References